Logo

NDRA

ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc. • NASDAQ
$5.91 ▼ -5.14% (-0.32)
Market Cap $4.45 M
52w High $11.96
52w Low $2.90
Dividend Yield 0%
P/E 0.3
Volume 42.55K
Outstanding Shares 752.63K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.331M ▲ $-1.596M ▼ 0% $-2.1 ▼ $-1.557M ▼
Q2-2025 $0 $1.268M ▼ $-1.226M ▼ 0% $-1.71 ▲ $-1.193M ▼
Q1-2025 $0 $1.424M ▼ $-1.036M ▲ 0% $-1.86 ▲ $-990.747K ▲
Q4-2024 $0 $4.25M ▲ $-4.149M ▼ 0% $-7.73 ▼ $-4.103M ▼
Q3-2024 $0 $1.509M $-2.354M 0% $-2.1 $-1.455M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $794.036K ▼ $1.964M ▼ $1.793M ▲ $171.38K ▼
Q2-2025 $1.809M ▼ $2.808M ▼ $1.335M ▼ $1.473M ▼
Q1-2025 $2.065M ▼ $3.171M ▼ $1.418M ▼ $1.753M ▼
Q4-2024 $3.229M ▼ $4.452M ▼ $1.892M ▲ $2.56M ▼
Q3-2024 $4.745M $8.379M $1.774M $6.605M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-1.226M ▼ $-1.114M ▲ $0 ▲ $857.415K ▲ $-256.3K ▲ $-1.114M ▲
Q1-2025 $-1.036M ▲ $-1.293M ▲ $-17.28K ▼ $145.803K ▲ $-1.165M ▲ $-1.31M ▲
Q4-2024 $-4.149M ▼ $-1.516M ▲ $0 $0 ▼ $-1.516M ▲ $-1.516M ▲
Q3-2024 $-2.354M ▼ $-1.657M ▲ $0 ▼ $1.683K ▼ $-1.656M ▼ $-1.657M ▲
Q2-2024 $-2.229M $-2.083M $11K $7.338M $5.266M $-2.072M

Five-Year Company Overview

Income Statement

Income Statement ENDRA is still a pre‑revenue company: it has not yet generated meaningful sales from its technology over the past several years. Operating costs and net losses have been fairly steady, reflecting an R&D‑driven, early‑stage profile rather than a scaled commercial business. Earnings per share look very negative largely because the share count has been repeatedly adjusted through reverse splits, not because losses have suddenly exploded in economic terms. Overall, the income statement tells the story of a company that is still in the development and validation phase, with the business model yet to be commercially proven.

Balance Sheet

Balance Sheet The balance sheet is extremely thin, with only a small base of assets and equity remaining and no traditional debt reported. This suggests that the company has been funding itself largely through equity issuance and then reverse splitting the stock to maintain listing standards. The lack of a sizable cash cushion or tangible asset base highlights financial fragility and a high reliance on future capital raises or partnership funding. From a solvency standpoint, the room for error appears limited: successful execution on regulatory and commercial milestones is particularly important given how light the balance sheet has become.

Cash Flow

Cash Flow Cash flow has been consistently negative as the company spends on operations and development while generating no revenue. There is essentially no spending on big physical assets, underscoring that most cash goes into people, trials, and technology rather than factories or heavy equipment. Because there is no internal cash generation, the business depends on external financing to keep operating, which can lead to ongoing shareholder dilution. The pattern is typical for a pre‑commercial medtech firm, but it also means the timing of regulatory approvals, partnerships, or licensing deals will heavily influence funding needs.

Competitive Edge

Competitive Edge ENDRA is trying to carve out a niche in liver imaging with a technology that aims to sit between cheap but rough ultrasound and expensive, high‑precision MRI. Its TAEUS system is designed as an add‑on to the vast installed base of ultrasound machines, which, if adopted, could help it scale without building a large hardware footprint from scratch. The company’s patent portfolio is extensive for its size, which can provide some defense against copycats and strengthen its bargaining power with partners. However, it still faces the dual challenge of proving clinical value versus established tools like FibroScan and MRI while also persuading conservative healthcare systems to change existing diagnostic workflows. Until it secures broad regulatory approvals and real‑world usage, its competitive position is more “promising concept” than established player.

Innovation and R&D

Innovation and R&D Innovation is the core of the ENDRA story: its thermo‑acoustic enhanced ultrasound aims to turn a familiar, low‑cost modality into a more quantitative tool for liver and potentially other tissues. The technology directly targets a large unmet need in non‑invasive liver fat measurement at the point of care, with potential spillover into areas like treatment monitoring for obesity and diabetes drugs. The company also outlines a broader roadmap—temperature monitoring in cancer procedures, blood‑flow assessment, and future versions that use AI and greater integration—to build a multi‑application platform rather than a single niche device. The main risk is execution: translating a strong patent and concept base into regulatory approvals, clinician adoption, and reimbursement is complex and uncertain, especially for a small company with limited financial resources.

Summary

ENDRA is a classic high‑risk, high‑uncertainty early‑stage medtech story: highly innovative technology, but no commercial traction yet and a very thin financial cushion. The income statement and cash flow profile show a business still in development mode, spending steadily without revenue, while the balance sheet reflects repeated reliance on equity markets, including multiple reverse stock splits. On the strategic side, the company is aiming at a large and growing problem—fatty liver disease and related conditions—and trying to position its technology as an affordable, quantitative imaging tool that could complement or partially replace more expensive diagnostics. Success would depend on clearing regulatory hurdles, demonstrating clear clinical and economic value, forming the right commercial partnerships, and maintaining funding through to meaningful adoption. Given these factors, outcomes range widely—from substantial impact if the technology is validated and adopted, to financial strain if milestones are delayed or the market proves harder to penetrate than expected.

NEWS

November 20, 2025 · 8:00 AM UTC

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Read more

November 17, 2025 · 8:00 AM UTC

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Read more

November 13, 2025 · 8:00 AM UTC

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Read more

October 23, 2025 · 8:00 AM UTC

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Read more

October 13, 2025 · 8:00 AM UTC

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Read more